Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

FDA approves first radioligand generic, setting up rivalry with Novartis

For the first time, Novartis’ leadership in the radioligand field will be tested by a generic rival. Curium announced on Monday that the FDA has approved its “radioligand equivalent” to Novartis’ Lutathera for the treatment ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Tuesday 15 September →